Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
EGFR Mutated Non-small Cell Lung Cancer Patients
Both
EGFR Mutated Non-small Cell Lung Cancer Patients
Trial Information
Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain
Observational retrospective study to describe the management of advanced or metastatic EGFR
mutated non-small cell lung cancer patients in Spain
Inclusion Criteria:
- Histologically or cytologically confirmed newly locally advanced or metastatic NSCLC
(stage IIIB/IV)
- Confirmed EGFR mutation by a validated test
- Availability of medical record
Exclusion Criteria:
- Participating on a blinded randomized clinical trial at any time during the study
period
- Pregnant women (due to they do not reflect daily clinical practice)
Type of Study:
Observational
Study Design:
Time Perspective: Retrospective
Outcome Measure:
Description of management patterns (clinical and diagnostic) of advanced/metastatic EGFR M+ NSCLC patients in Spain.
Outcome Time Frame:
32 months
Safety Issue:
No
Authority:
Spain: Spanish Agency of Medicines
Study ID:
NIS-OES-XXX-2012/1
NCT ID:
NCT01795352
Start Date:
March 2013
Completion Date:
September 2013
Related Keywords:
- EGFR Mutated Non-small Cell Lung Cancer Patients
- EGFR,
- lung cancer,
- mutated
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
